Inmedix CEO to Co-Chair Study Group Highlighting Autonomic Nervous System (ANS) Effect on Autoimmune Disease Treatment Success at ACR/ARHP Annual Meeting 2016

Inmedix CEO & Co-founder, Andrew J. Holman, MD, will co-chair the ACR study group "Autonomic Neuroregulation of Autoimmune Disease" with Paul-Peter Tak, MD, PhD, Chief Immunology Officer & Senior Vice President R&D Pipeline at GlaxoSmithKline (GSK), during ACR/ARHP Annual Meeting 2016, being held November 11-16, 2016 at Walter E. Washington Convention Center, Washington DC

Seattle, Washington (PRWEB) November 09, 2016 -- Inmedix, the leader in heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, today announced that CEO & Co-founder, Andrew J. Holman, MD, will co-chair the ACR study group "Autonomic Neuroregulation of Autoimmune Disease" with Paul-Peter Tak, MD, PhD, Chief Immunology Officer & Senior Vice President R&D Pipeline at GlaxoSmithKline (GSK), during ACR/ARHP Annual Meeting 2016, being held November 11-16, 2016 at Walter E. Washington Convention Center, Washington DC. Also, speaking will be Carolina Kagan, MSc, regulatory scientist, reviewing pre- and post-market applications in the FDA's Center for Devices and Radiological Health (CDRH), the Office of in Vitro Diagnostics and Radiological Health (OIR) and Division of Immunology and Hematology Devices (DIHD).

This 2016 study group follows the first-of-its-kind ACR study group in 2015 to examine how the brain regulates the immune system to affect rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and other autoimmune diseases. Innovative applications of this area of research will be discussed by the speakers and audience to develop better treatments, prediction and prevention of autoimmune diseases.

Stress, controlled in the brain by the autonomic nervous system (ANS), appears to intensify RA and SLE flares to provide a new metric to more comprehensively understand how the disease is expressed in individual patients. Understanding how this component of the brain differs from person to person may be an important expansion in the concept of personalized, precision medicine. While genomics also contributes, the ANS may be more immediately actionable to mitigate its adverse effect on immune-mediated disease activity. It is hypothesized that this concept offers a potentially new way to address immune-mediated disease, especially autoimmune disease.

"The ANS controls fight-or-flight stress responses which affect immune function," says Andrew J. Holman, MD, Inmedix CEO, Associate Professor of Medicine at the University of Washington and rheumatologist. "While necessary for survival, its activation in the setting of an autoimmune disease is akin to injecting oxygen into a flame. We all hope for a magic bullet to neutralize the cause of RA, SLE and other autoimmune diseases but until that is discovered, awareness of how the brain adversely affects these diseases may offer a promising path in the near-term to further reduce the disease burden borne by our patients."

About Inmedix, LLC
Seattle-based biotech Inmedix is committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the autonomic nervous system (ANS). Inmedix's ANS Neuroscan is the leading heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, beginning with U.S. patients with rheumatoid arthritis (RA). The company's science and technology raises

PRWeb ebooks - Another online visibility tool from PRWeb

therapeutic outcomes and retention so that patients no longer need to cycle through failure of one biologic after another. Visit http://www.inmedix.com

Media Contact:
Rae Marie Gleason
714-423-4863
raemarie.gleason(at)inmedix(dot)com

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb

Contact Information
Jeff Denenholz
JDenny Communications
+1 (206) 437-9810

Online Web 2.0 Version
You can read the online version of this press release here.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb